NO873492L - Fremgangsmaate for fremstilling av antifungale preparater. - Google Patents

Fremgangsmaate for fremstilling av antifungale preparater.

Info

Publication number: NO873492L
Authority: NO; Norway
Prior art keywords: vesicles; fungal infections; procedure; preparation; systemic fungal
Prior art date: 1986-08-21

Application number

NO87873492A

Other languages

English (en)

Other versions

NO873492D0 (no

NO174833C (no

NO174833B (no

Inventor

Jill Adler-Moore

Ronald Carl Gamble

Richard Thomas Proffitt

Original Assignee

Vestar Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-08-19

Publication date

1988-02-22

1987-08-19 Application filed by Vestar Inc filed Critical Vestar Inc

1987-08-19 Publication of NO873492D0 publication Critical patent/NO873492D0/no

1988-02-22 Publication of NO873492L publication Critical patent/NO873492L/no

1994-04-11 Publication of NO174833B publication Critical patent/NO174833B/no

1994-07-20 Publication of NO174833C publication Critical patent/NO174833C/no

Links

230000000843 anti-fungal effect Effects 0.000 title abstract 4
229940121375 antifungal agent Drugs 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 2
206010017533 Fungal infection Diseases 0.000 abstract 2
208000031888 Mycoses Diseases 0.000 abstract 2
230000003115 biocidal effect Effects 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Medical Informatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO873492A 1986-08-21 1987-08-19 Fremgangsmåte for fremstilling av et injiserbart preparat NO174833C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89906486A	1986-08-21	1986-08-21

Publications (4)

Publication Number	Publication Date
NO873492D0 NO873492D0 (no)	1987-08-19
NO873492L true NO873492L (no)	1988-02-22
NO174833B NO174833B (no)	1994-04-11
NO174833C NO174833C (no)	1994-07-20

Family

ID=25410437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873492A NO174833C (no)	1986-08-21	1987-08-19	Fremgangsmåte for fremstilling av et injiserbart preparat

Country Status (14)

Country	Link
US (1)	US5874104A (no)
EP (1)	EP0260811B1 (no)
JP (1)	JPH0615475B2 (no)
KR (1)	KR950013747B1 (no)
AT (1)	ATE66597T1 (no)
AU (1)	AU606880B2 (no)
CA (1)	CA1292184C (no)
DE (1)	DE3772498D1 (no)
DK (1)	DK168982B1 (no)
ES (1)	ES2051740T3 (no)
GR (1)	GR3002852T3 (no)
HK (1)	HK115393A (no)
IE (1)	IE60901B1 (no)
NO (1)	NO174833C (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2620028B2 (fr) *	1986-12-05	1994-02-25	Ire Celltarg Sa	Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
US4999199A (en) *	1988-11-10	1991-03-12	Board Of Regents, The University Of Texas System	Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
WO1991007973A1 (fr) *	1989-11-27	1991-06-13	Nippon Shinyaku Co., Ltd.	Emulsion grasse
CA2099772A1 (en) *	1991-01-14	1992-07-15	Gabriel Lopez-Berestein	Anti-hiv activity of liposomal nystatin and amphotericin b
WO1993007884A1 (en) *	1991-10-25	1993-04-29	Senju Pharmaceutical Co., Ltd.	External preparation for treating hemorrhoidal diseases
JP2915296B2 (ja) *	1993-08-30	1999-07-05	宇野潤	抗真菌製剤
GB9519654D0 (en) *	1995-09-27	1995-11-29	Nycomed Imaging As	Stabilised phospholipid compositions
PL328199A1 (en)	1996-01-25	1999-01-18	Schering Ag	Improved concentrated intravascular injection and infusion solutions
GB9721901D0 (en) *	1997-10-16	1997-12-17	Univ Manchester	Particles
AU1350099A (en) *	1997-12-01	1999-06-16	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Formulations for topical treatment of skin infections
IT1301807B1 (it) *	1998-06-25	2000-07-07	Tiberio Bruzzese	Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US6413537B1 (en)	2000-03-10	2002-07-02	Wisconsin Alumni Research Foundation	Nystatin formulation having reduced toxicity
JP4786041B2 (ja) *	2001-03-02	2011-10-05	丸善製薬株式会社	渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) *	2002-11-15	2010-01-26	Albert Einstein College Of Medicine Of Yeshiva University	Methods of applying ionization radiation for therapy of infections
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US20070191272A1 (en) *	2005-09-27	2007-08-16	Stemmer Willem P	Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
RU2008122978A (ru)	2005-11-09	2009-12-20	Комбинаторкс, Инкорпорейтед (Us)	Способы, композиции и наборы для лечения медицинских состояний
US20070190127A1 (en)	2005-12-30	2007-08-16	Mingdong Zhou	Extended release of neuregulin for improved cardiac function
KR20100058541A (ko) *	2007-08-15	2010-06-03	아뮤닉스 인코포레이티드	생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
ES2630036T3 (es)	2008-03-06	2017-08-17	Anacor Pharmaceuticals, Inc.	Moléculas pequeñas que contienen boro como agentes antiinflamatorios
ES2730800T3 (es) *	2009-02-03	2019-11-12	Amunix Pharmaceuticals Inc	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
DK2440228T3 (en)	2009-06-08	2018-12-17	Amunix Operating Inc	Glucose regulating polypeptides and methods for their preparation and use
CN106916229A (zh)	2009-06-08	2017-07-04	阿穆尼克斯运营公司	生长激素多肽及其制备和使用方法
EP3485881B1 (en)	2009-07-10	2024-03-13	President and Fellows of Harvard College	Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
BRPI1003990B1 (pt) *	2009-10-16	2021-09-14	Lifecare Innovations Pvt. Ltd	Formulação para o tratamento de infecções fúngicas
AU2010313456A1 (en)	2009-10-30	2012-05-17	Ntf Therapeutics, Inc.	Improved neurturin molecules
US20130109674A1 (en)	2009-12-18	2013-05-02	Achelios Therapeutics Llc	Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8716478B2 (en)	2010-01-27	2014-05-06	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
EP2668961A4 (en) *	2010-11-19	2016-07-06	Univ Sapporo Medical	PHARMACEUTICAL COMBINATION PREPARATION
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
SI3564260T1 (sl)	2012-02-15	2023-02-28	Bioverativ Therapeutics Inc.	Sestavki faktorja VIII in postopki njegove izdelave in uporabe
WO2013184938A2 (en)	2012-06-08	2013-12-12	Alkermes. Inc.	Fusion polypeptides comprising mucin-domain polypeptide linkers
EP3033097B1 (en)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Factor viii-xten fusions and uses thereof
CN107124869B (zh)	2014-03-25	2022-04-01	美国政府陆军部	包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂
CN107614061A (zh)	2014-12-01	2018-01-19	阿科莱尔斯疗法公司	用于治疗与疼痛有关的偏头痛和病症方法和组合物
CA2994545A1 (en)	2015-08-03	2017-02-09	President And Fellows Of Harvard College	Charged ion channel blockers and methods for use
CN108472337B (zh)	2015-08-03	2022-11-25	比奥贝拉蒂治疗公司	因子ix融合蛋白以及其制备和使用方法
SG11201803594TA (en)	2015-11-06	2018-05-30	Adjuvance Technologies Inc	Triterpene saponin analogues
EP3500581A4 (en)	2016-08-17	2021-10-06	Solstice Biologics, Ltd.	POLYNUCLEOTIDE CONSTRUCTS
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
JP2020536946A (ja)	2017-10-16	2020-12-17	アジュバンス・テクノロジーズ・インコーポレーテッド	トリテルペンサポニン類似物
JP2022525856A (ja)	2019-03-11	2022-05-20	ノシオンセラピューティクス，インコーポレイテッド	荷電したイオンチャンネル遮断薬および使用方法
US10786485B1 (en)	2019-03-11	2020-09-29	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
KR20210145164A (ko)	2019-03-11	2021-12-01	녹시온 테라퓨틱스 인코포레이티드	에스테르 치환된 이온 채널 차단제 및 사용 방법
US10780083B1 (en)	2019-03-11	2020-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CA3129117A1 (en)	2019-03-11	2020-09-17	Bridget Mccarthy Cole	Charged ion channel blockers and methods for use
EP4054586A4 (en)	2019-11-06	2023-11-22	Nocion Therapeutics, Inc.	CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
IL292505A (en)	2019-11-06	2022-06-01	Nocion Therapeutics Inc	Charged ion channel blockers and methods of use
AU2021236130A1 (en)	2020-03-11	2022-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
WO2023175454A1 (en)	2022-03-14	2023-09-21	Pfizer Inc.	Methods for producing an adjuvant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310505A (en) *	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) *	1983-02-10	1985-02-05	Vestar Research Incorporated	Method for labeling phagocytic cells
GB2135647A (en) *	1983-02-15	1984-09-05	Squibb & Sons Inc	Method of preparing liposomes and products produced thereby
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
IE58659B1 (en) *	1984-10-22	1993-11-03	Vestar Inc	Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors
US4753788A (en) *	1985-01-31	1988-06-28	Vestar Research Inc.	Method for preparing small vesicles using microemulsification
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin

1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-14 EP EP87307221A patent/EP0260811B1/en not_active Expired - Lifetime
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active IP Right Cessation
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/xx not_active IP Right Cessation
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GR3002852T3 (en)	1993-01-25
AU7716087A (en)	1988-02-25
IE60901B1 (en)	1994-08-24
EP0260811A2 (en)	1988-03-23
EP0260811A3 (en)	1988-07-20
DK168982B1 (da)	1994-07-25
DK434187A (da)	1988-02-22
ES2051740T3 (es)	1994-07-01
KR880002531A (ko)	1988-05-09
AU606880B2 (en)	1991-02-21
DE3772498D1 (de)	1991-10-02
CA1292184C (en)	1991-11-19
DK434187D0 (da)	1987-08-20
NO873492D0 (no)	1987-08-19
JPS6366123A (ja)	1988-03-24
NO174833C (no)	1994-07-20
NO174833B (no)	1994-04-11
IE872148L (en)	1988-02-21
US5874104A (en)	1999-02-23
KR950013747B1 (ko)	1995-11-15
EP0260811B1 (en)	1991-08-28
JPH0615475B2 (ja)	1994-03-02
ATE66597T1 (de)	1991-09-15
HK115393A (en)	1993-11-05

Legal Events

Date	Code	Title	Description
2007-08-27	MK1K	Patent expired

Publication	Publication Date	Title
NO873492D0 (no)	1987-08-19	Fremgangsmaate for fremstilling av antifungale preparater.
AU587232B2 (en)	1989-08-10	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
AU8141791A (en)	1991-11-07	Method for determining unentrapped ionizable bioactive agents in liposome preparations
GR1000074B (el)	1990-10-31	Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
CA2233961A1 (en)	1997-04-10	Stimulation of hair follicles
NO901852D0 (no)	1990-04-26	Fremgangsmaate for fremstilling av liposomer.
NO180147C (no)	1997-02-26	Fremgangsmåte for fremstilling av HDLC eller et liposom innbefattende et polyen-antisopp-antibiotikum og et lipid
KR950700725A (ko)	1995-02-20	리포솜 조성물(liposome composition)
RU94027343A (ru)	1996-09-27	Липосомальная везикула с цитохромом с